Available online www.jsaer.com

***Journal of Scientific and Engineering Research*, 2021, 8(8):186-189**

Research Article

ISSN: 2394-2630
CODEN(USA): JSERBR

Analytical Models for Physician Segmentation in the Pharmaceutical Industry: A Review and Evaluation

Nazim N Haider

Abstract This paper provides a comprehensive overview of analytical models used in physician segmentation in the pharmaceutical industry, with a particular focus on rare diseases. Key insights include the significance of techniques such as cluster analysis, factor analysis, and regression models in understanding physician behavior and preferences, the challenges posed by limited data access and biases in segmentation models, and the importance of leveraging advanced analytics like machine learning and artificial intelligence to enhance predictive power and tailor marketing strategies. The paper underscores the critical role of physician segmentation in rare diseases, emphasizing the need for personalized approaches and innovative methods to improve accuracy in identifying key opinion leaders, understanding referral networks, and ultimately enhancing patient care and treatment outcomes.

Keywords Analytical models, predictive modeling, personalized segmentation, targeted marketing

Introduction And Background

Analytical models play a pivotal role in physician segmentation in the pharmaceutical industry, enabling companies to analyze vast datasets and identify patterns that categorize healthcare providers based on various criteria. These models offer a systematic approach to segmenting physicians according to factors such as specialty, patient demographics, prescribing behavior, and practice settings. By leveraging advanced analytical techniques, pharmaceutical companies can gain valuable insights into physician behavior, preferences, and interactions, allowing targeted marketing strategies, resource optimization, and tailored engagement initiatives to enhance the effectiveness of promotional efforts and improve patient outcomes [2].

The purpose of this paper is to review the different analytical models used in physician segmentation and identify the gaps. The paper also attempts to understand and evaluate physician segmentation in rare diseases.

Literature Review

Analytical Models Used for Physician Segmentation

Some analytical models commonly used for physician segmentation include cluster analysis, factor analysis, regression models, decision trees, and predictive modeling. With advancements in Machine Learning (ML) and Artificial Intelligence (AI) tools, companies can combine these methods to build ML models for segmentation.

- Cluster Analysis: Cluster analysis is a statistical technique used to group physicians with similar characteristics and prescribing behaviors into clusters or segments. It aims to identify natural groupings within a dataset without prior knowledge of the group membership. In the context of physician segmentation, cluster analysis can be used to identify groups of healthcare providers who exhibit similar patterns of behavior, prescribing habits, patient interactions, or practice characteristics. By clustering physicians based on these attributes, companies can create distinct segments for targeted marketing strategies. The output of the cluster analysis is a set of clusters or segments, each containing a group of

physicians who share common characteristics. These segments are mutually exclusive, and physicians within the same cluster are more similar to each other than to those in the other clusters. Cluster analysis has some challenges, such as the subjective selection of clustering variables and methods that can impact segmentation results; interpretation of cluster results may require additional analysis to understand the characteristics of each segment, and sensitivity to outliers and noise in the data can affect cluster formation [3].

- Factor Analysis: Factor analysis is a statistical method used to identify underlying factors or latent variables that explain the correlations among the observed variables. It aims to reduce the dimensionality of a dataset by identifying the common factors that account for observed variance. In physician segmentation, factor analysis can be used to identify the underlying dimensions or factors that drive physician behavior, preferences, or attitudes. By uncovering these latent variables, companies can reduce the complexity of the data and identify key factors that differentiate physician segments. The output of the factor analysis is a set of factors or latent variables that represent the underlying structure of the data. These factors can be used to create composite scores or indices that capture the shared variance among observed variables [3].
- Regression Analysis: Regression analysis is used to examine the relationship between one or more independent variables (such as physician demographics, prescribing behavior, and practice characteristics) and a dependent variable (such as prescription volume, brand loyalty, and patient referrals). Regression analysis helps to identify the impact of specific variables on physician behavior and can be used to predict outcomes based on these variables. It focuses more on understanding the influence of individual factors on physician segmentation. Some challenges of regression analysis are that it assumes a linear relationship between variables, which may not always hold true and is limited in capturing complex interactions and patterns in data requiring careful selection of variables and model specification [3].

In practice, a combination of both regression analysis and cluster analysis can provide a comprehensive understanding of physician segmentation, with regression analysis focusing on relationships between variables and outcomes and cluster analysis identifying natural groupings within the physician population. The choice between regression analysis and cluster analysis depends on the specific objectives, data characteristics, and desired segmentation outcomes in the pharmaceutical industry. Furthermore, cluster analysis is more suitable for creating distinct segments for targeted marketing, whereas factor analysis is more useful for understanding the underlying dimensions that influence physician behavior and preferences. In physician segmentation, all these methods can be valuable tools, depending on the research objectives and nature of the data [4].

Gaps in Modeling Techniques

A few challenges influence the accuracy of these modeling techniques. A key challenge in physician segmentation is the availability of comprehensive and accurate data. Pharmaceutical companies may face limitations in accessing real-time data on physician behavior, preferences, and patient interactions, leading to gaps in the segmentation models. Many segmentation models in the pharmaceutical industry rely on static variables such as specialty, geographic location, or prescription volume. This static approach overlooks dynamic factors that influence physician behavior, such as evolving treatment guidelines, emerging therapies, or changes in patient demographics. There is a lack of integration between the different data sources and systems used for physician segmentation. Siloed data and fragmented systems can result in inconsistencies, duplication of efforts, and inefficiencies in segmentation modeling, leading to suboptimal targeting strategies [1]. In addition, segmentation models can be susceptible to bias or assumptions that can affect the accuracy and fairness of targeting healthcare providers. Biases in data collection, analysis, or interpretation can lead to misclassification by physicians and ineffective segmentation outcomes. Some segmentation models also lack predictive power for identifying future trends, behaviors, or preferences among physicians. Without robust predictive capabilities, pharmaceutical companies may struggle to anticipate changes in the market landscape and accordingly adjust their segmentation strategies. To address the gaps in physician segmentation models used in the pharmaceutical industry, companies can leverage advanced analytics techniques such as machine learning, predictive modeling, and artificial intelligence to enhance the predictive power of segmentation models. Companies should encourage moving towards personalized segmentation strategies that tailor marketing approaches to individual physicians,

based on their unique characteristics and preferences. Implement segmentation models that can create customized messaging, content, and engagement strategies for different healthcare providers [3].

Physician Segmentation for Rare Diseases

Physician segmentation of rare diseases plays a critical role in pharmaceutical marketing and patient care. Physician segmentation helps to identify key opinion leaders (KOLs) in the field of rare diseases with expertise and influence in diagnosing and managing these conditions. By targeting KOLs through segmentation, pharmaceutical companies can engage with thought leaders who advocate for new treatments, participate in clinical trials, and educate their peers about rare diseases. Physician segmentation can also support clinical trial recruitment for rare diseases. By identifying physicians with a patient population that may be eligible for clinical trials, pharmaceutical companies can engage with these healthcare providers to facilitate patient referrals, increase trial enrollment, and accelerate the development of new therapies for rare diseases.

However, physician segmentation for rare diseases presents unique challenges owing to the limited number of patients and physicians involved. Rare diseases affect a small number of individuals, thereby limiting and dispersing the patient population [5]. Rare diseases often require specialized knowledge and expertise for accurate diagnosis and treatment. The pool of healthcare providers with experience in managing rare diseases is limited, making it challenging to identify and segment physicians with knowledge and experience in treating these conditions. In addition, physicians with expertise in rare diseases may be geographically dispersed, especially in regions with small populations or limited healthcare resources. This dispersion complicates the segmentation process because targeting these specialists requires a thorough understanding of their locations and practice settings [6]. Pharmaceutical companies can employ specialized segmentation strategies tailored to this niche market to effectively target physicians treating rare diseases. The first step in physician segmentation for rare diseases is to identify physicians treating diagnosed or underdiagnosed rare disease patients. This may involve analyzing medical claims data, prescription data, or disease registries to identify physicians with a history of treating rare diseases. Rare diseases often have imbalanced classes in the dataset, making it challenging to accurately predict the identities of rare disease physicians. Techniques such as oversampling, under sampling, and probabilistic graphical models can help overcome the imbalance problem and improve the targeting accuracy. To improve the predictive power of physician segmentation for rare diseases, companies can also consider adding covariance to account for feature correlations, incorporating extensive historical treatment data for each physician, and exploring innovative methods to tackle the challenges of predicting the physician identity of rare diseases. Owing to the complex diagnostic pathways, physician segmentation for rare diseases needs to account for the interactions among different healthcare professionals involved in the diagnostic process [7]. Referral networks play a crucial role in connecting patients with rare diseases to healthcare providers with necessary expertise. Physician segmentation for rare diseases must consider the dynamics of patient referrals, collaborations among healthcare professionals, and the influence of key opinion leaders in the field. Graphical models, such as factor graphs or Markov random fields, can be utilized to structurally model physician-patient features and leverage relational information to improve target identification accuracy. These models can capture dependencies among physicians, patients, and physician-patient relationships, leading to more accurate segmentation for rare diseases. Probabilistic graphical models formulate the physician classification problem using a probabilistic joint distribution [4]. These models depict the dependence structure between physicians and patients, relaxing the assumption of independence and improving the accuracy of target label prediction for rare diseases.

Conclusion

This paper highlights the critical role of advanced analytical models in physician segmentation within the pharmaceutical industry, emphasizing their importance in understanding physician behavior, preferences, and interactions. By reviewing techniques such as cluster analysis, factor analysis, and predictive modeling, along with addressing gaps in current segmentation models, the paper underscores the need for personalized and data-driven approaches to enhance targeted marketing strategies and improve patient outcomes. Specifically focusing on rare diseases, the paper emphasizes the challenges and complexities involved in segmenting physicians in

this niche area, advocating for the adoption of innovative methods such as probabilistic graphical models to improve accuracy and effectiveness in identifying key opinion leaders and optimizing patient referrals.

Reference

[1]. Singh, H., & Mittal, K. (2010). PRESCRIBERS SEGMENTATION-STRATEGY FOR PHARMACEUTICAL CORPORATIONS SUCCESS. International Journal of Research in Commerce and Management. https://doi.org/10.20968/RPM/2010/V8/I1/92854.

[2]. Hersh, W., Weiner, M., Embí, P., Logan, J., Payne, P., Bernstam, E., Lehmann, H., Hripcsak, G., Hartzog, T., Cimino, J., & Saltz, J. (2013). Caveats for the use of operational electronic health record data in comparative effectiveness research. Medical care, 51 8 Suppl 3, S30-7. https://doi.org/10.1097/MLR.0b013e31829b1dbd.

[3]. Kumar, L., & Panigrahi, C. (2014). Communication with Doctors: Empowering Pharma Field Force With Modern Marketing Techniques. Managerial Marketing eJournal.

[4]. Cai, Y., Liu, Q., Shi, C., Wang, Y., & Zhang, F. (2020). Rare Disease Detection and Physician Targeting: A Factor Graph Machine Learning approach. Social Science Research Network. https://doi.org/10.2139/ssrn.3546969

[5]. Kesselheim, A. S., & Gagne, J. J. (2014). Strategies for postmarketing surveillance of drugs for rare diseases. Clinical pharmacology and therapeutics, 95(3), 265–268. https://doi.org/10.1038/clpt.2013.218

[6]. Schieppati, A., Henter, J. I., Daina, E., &Aperia, A. (2008). Why rare diseases are an important medical and social issue. Lancet (London, England), 371(9629), 2039–2041. https://doi.org/10.1016/S0140-6736(08)60872-7

[7]. Gliklich, R. E., Dreyer, N. A., & Leavy, M. B. (Eds.). (2014). Registries for Evaluating Patient Outcomes: A User's Guide. (3rd ed.). Agency for Healthcare Research and Quality (US).